新型抗肿瘤药治疗血液肿瘤的的研究进展

Progress of novel antineoplastic drugs in the treatment of hematologic malignancy

随着分子生物学技术的发展,血液肿瘤领域的治疗方式上实现了跨时代的革新与突破。小分子酪氨酸激酶抑制剂——伊马替尼于2001年经FDA批准上市,就此血液肿瘤的治疗开启了小分子靶向药物的时代。在过去20年里,血液肿瘤治疗迈入了个性化精准治疗的新时代。除了小分子药物以外,免疫治疗也使血液肿瘤治疗的模式产生了巨大变化。这类药物特异性地杀伤肿瘤细胞,将化疗主导血液肿瘤治疗的传统格局打破,化疗时代治疗过程中所引起的毒副作用明显减少,患者的耐受性得到很大的提高。同时,免疫治疗技术日趋成熟,越来越多地应用于临床患者。新型药物间联合应用等新的治疗策略不断涌现,使我们的临床患者获得了更优异的疗效。

With the development of molecular biology technology,the treatment of hematological maligancy has achieved the innovation and breakthrough of the era.Imatinib,a small-molecule tyrosine kinase inhibitor,was approved by the FDA in 2001,ushering in the era of small-molecule targeted drugs.In the past two decades,hematologic malignancy treatment has entered a new era of personalized accurate therapy.In addition to target therapies,immunological therapies have dramatically changed the way of hematologic malignancy treatments.This kind of drugs specifically kill tumor cells,breaking the traditional pattern of chemotherapy treatment of hematologic tumors Therefore,the side effects of chemotherapy are significantly reduced,and the tolerance of the patients has been greatly improved.At the same time,immunotherapy technology is becoming more and more mature and applied to clinical patients.Combinations of targeted agents are now being investigated to improve effectiveness.New therapeutic strategies,such as novel drug combinations,have enabled our clinical patients to achieve better outcomes.